ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1299

Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study

Edward Keystone1, Juan Xiong2, Deborah Weber3 and Ye Sun4, 1The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a biologic with a different mode of action such as rituximab (RTX) or abatacept (ABA). The relative effectiveness of these approaches has not been determined in head-to-head trials. Evidence from real-world experience would help to guide treatment decisions for TNF-IR patients.

Methods: This was a retrospective chart review of patients from a single site (Rebecca MacDonald Center) with ACR-defined RA who initiated RTX or ABA after failure of at least one TNFi. The relative effectiveness of RTX and ABA was evaluated by analyzing drug survival distribution. Kaplan-Meier survival curves were compared using the log rank test (p-values <0.05 indicated statistical significance).

Results: The study cohort comprised 61 patients, of whom 37 and 24 were treated with RTX and ABA, respectively. In the RTX group, 10 patients had also received prior therapy with ABA. Demographics and disease characteristics were generally similar in the two groups, although RTX patients had higher disease activity compared with ABA patients (mean CDAI: RTX 32.5 vs ABA 26.9) and had received more prior TNFis (1.8 vs 1.7) and/or ABA (2.1 vs 1.7). After excluding the 10 RTX patients who had received prior ABA, survival rates over time were generally better with RTX vs ABA (table).

Estimated survival rates

Time (years)

RTX (n=27)

ABA (n=24)

0.5

0.92

0.83

1.0

0.79

0.74

1.5

0.74

0.54

2.0

0.68

0.54

3.0

0.68

0.54

4.0

0.68

0.41

Overall survival distribution (figure) was not significantly different between the RTX and ABA groups (p=0.658); however, RTX patients who had also failed ABA had significantly reduced survival compared with those who had not received ABA (p=0.015).

Overall survival distribution

Stratification of survival data according to number of prior TNFi failures indicated that RTX (excluding patients with prior ABA) was superior to ABA among patients who had failed 3 TNFis. Survival was also numerically greater with RTX vs ABA in patients who had failed 1 prior TNFi. Finally, survival was better on both RTX and ABA when compared with that seen in a separate cohort of patients (n=88) who received a second TNFi after first TNFi failure.

Conclusion: These results from real-life practice suggest that in RA patients who have failed one or more TNFi, RTX may have better long-term survival than either ABA or an alternative TNFi. Prior ABA appears to reduce the efficacy of RTX. Further data are needed.


Disclosure:

E. Keystone,

Abbott, Amgen, AstraZeneca, Bristol-Meyers Squibb, Centocor, Roche, Genzyme, Merck, Novartis, Pfizer, UCB,

2,

Abbott, AstraZeneca, Biotest, Bristol-Meyers Squibb, Centocor, Roche, Genentech, Merck, Nycomed, Pfizer, UCB,

5;

J. Xiong,
None;

D. Weber,
None;

Y. Sun,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-versus-abatacept-in-rheumatoid-arthritis-patients-with-an-inadequate-response-to-prior-biologic-therapy-a-retrospective-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology